255 related articles for article (PubMed ID: 15860372)
1. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
Berkers CR; Ovaa H
Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
[TBL] [Abstract][Full Text] [Related]
2. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
3. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
4. The in vivo response of invariant natural killer T cells to glycolipid antigens.
Parekh VV; Lalani S; Van Kaer L
Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
Miyake S; Yamamura T
Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
[TBL] [Abstract][Full Text] [Related]
6. The immunoregulatory role of CD1d-restricted natural killer T cells in disease.
van der Vliet HJ; Molling JW; von Blomberg BM; Nishi N; Kölgen W; van den Eertwegh AJ; Pinedo HM; Giaccone G; Scheper RJ
Clin Immunol; 2004 Jul; 112(1):8-23. PubMed ID: 15207777
[TBL] [Abstract][Full Text] [Related]
7. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
[TBL] [Abstract][Full Text] [Related]
9. Species-specific activity of glycolipid ligands for invariant NKT cells.
Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
[TBL] [Abstract][Full Text] [Related]
10. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.
Denkberg G; Stronge VS; Zahavi E; Pittoni P; Oren R; Shepherd D; Salio M; McCarthy C; Illarionov PA; van der Merwe A; Besra GS; Dellabona P; Casorati G; Cerundolo V; Reiter Y
Eur J Immunol; 2008 Mar; 38(3):829-40. PubMed ID: 18253930
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells.
Chen S; Ndhlovu LC; Takahashi T; Takeda K; Ikarashi Y; Kikuchi T; Murata K; Pandolfi PP; Riccardi C; Ono M; Sugamura K; Ishii N
Eur J Immunol; 2008 Aug; 38(8):2229-40. PubMed ID: 18624295
[TBL] [Abstract][Full Text] [Related]
12. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
13. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
14. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
15. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
16. Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts.
Lang GA; Maltsev SD; Besra GS; Lang ML
Immunology; 2004 Jul; 112(3):386-96. PubMed ID: 15196206
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells.
Brossay L; Naidenko O; Burdin N; Matsuda J; Sakai T; Kronenberg M
J Immunol; 1998 Nov; 161(10):5124-8. PubMed ID: 9820479
[TBL] [Abstract][Full Text] [Related]
18. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
19. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.
Miyamoto K; Miyake S; Yamamura T
Nature; 2001 Oct; 413(6855):531-4. PubMed ID: 11586362
[TBL] [Abstract][Full Text] [Related]
20. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.
Yu KO; Im JS; Illarionov PA; Ndonye RM; Howell AR; Besra GS; Porcelli SA
J Immunol Methods; 2007 May; 323(1):11-23. PubMed ID: 17442335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
